نتایج جستجو برای: roflumilast
تعداد نتایج: 449 فیلتر نتایج به سال:
We read with interest the Point and Counterpoint editorials in CHEST (May 2014) by Suissa and Rabe 1 and Rho et al 2 about the appropriateness of industry-sponsored rofl umilast trials. In the editorials, reference was made to the level of patient withdrawal as well as to the level of side eff ects experienced by patients receiving this drug during clinical trials. 2 In our real-world clinical ...
Oral phosphodiesterase (PDE) 4 inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases. However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea. Delivering the inhibitor by the inhaled route may improve therapeutic index, and herein we describe GSK256066 (6-({3[(dimethylamino) carb...
Oral phosphodiesterase (PDE) 4 inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases. However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea. Delivering the inhibitor by the inhaled route may improve therapeutic index, and herein we describe GSK256066 (6-({3[(dimethylamino) carb...
Oral phosphodiesterase (PDE) 4 inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases. However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea. Delivering the inhibitor by the inhaled route may improve therapeutic index, and we describe 6-({3-[(dimethylamino)carbonyl]phenyl}sulfon...
Current drug treatments for chronic obstructive pulmonary disease (COPD) focus on managing symptoms of the disease and include shortand long-acting b2-agonists, anticholinergic agents (ipratroprium, tiotropium), methylxanthines (theophylline) and inhaled corticosteroids (ICS). Cyclic nucleotide phosphodiesterases (PDEs) play a key role in cell signalling by degrading cyclic adenosine monophosph...
9 inhibitors are attractive targets for drug devel‐ opment. PDE4, for example, is one of the main enzymes involved in meta bolism and inflamma‐ tion within the airways.6 Thus, there has been a considerable inter est in PDE4 inhibitors in air‐ way disease, first with cilomilast and current‐ ly with roflumilast. The previous smaller stud‐ ies with cilomilast showed a beneficial effect on lung fun...
BACKGROUND Patients with COPD show a significant reduction of the lobar hyperinflation at the functional residual capacity level in the patients who improved >120 mL in forced expiratory volume in 1 second (FEV1) after 6 months of treatment with roflumilast in addition to inhaled corticosteroids (ICSs)/long-acting beta-2 agonists (LABAs)/long-acting muscarinic antagonists (LAMAs). METHODS Fun...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید